Absci Corporation, a company specializing in generative AI drug creation, has expanded into the European pharmaceutical market by opening its Innovation Center in Zug, Switzerland. The Zug Innovation Center will bring Absci's AI drug creation platform to the global stage and connect with the European pharma and biotech ecosystem. Absci has appointed two senior executives to lead its drug creation team: Christine Lemke, DVM, MBA, SVP of Portfolio & Growth Strategy, and Christian Stegmann, Ph.D., SVP of Drug Creation.
According to Andreas Busch, Absci's Chief Innovation Officer, the opening of the Zug Innovation Center marks a new phase in expanding the company's strategic R&D portfolio and building its own drug development pipeline. The center will leverage potential partners, global talent, and AI capabilities in Europe and beyond. Drs. Lemke and Stegmann will bring their extensive experience and impressive track record to lead Absci's strategic portfolio and global expansion.
Sean McClain, founder and CEO of Absci, believes that the Zug Innovation Center will bring the company's drug creation platform to the heart of European innovation. Zug is a leading biotech hub for bringing drugs to market, and Absci will tap into its talent and technology ecosystem to realize its mission of bringing life-changing biologics to patients faster through generative AI.
Dr. Lemke brings substantial corporate development and operations expertise to Absci, having previously served as Head of Global Corporate Development at Ferring International Center SA. Her experience in nearly every aspect of drug discovery and development will shape Absci's R&D strategy with a focus on bringing life-changing medicines to patients.
Dr. Stegmann is an accomplished R&D leader with a track record of successfully bringing novel molecules into clinical development. His previous roles include VP of Research and Non-clinical Development at CSL Vifor and various R&D leadership positions at Bayer. He believes that generative AI has the potential to power the next era of drug creation and looks forward to using Absci's unique capabilities to make the endeavor more efficient and successful, improving patients' lives.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!